Finding blood markers for Adrenomyeloneuropathy
Discovery and validation of multi-omic plasma biomarkers for Adrenomyeloneuropathy
This study is looking for new blood tests that can help track how Adrenomyeloneuropathy (AMN) changes over time and predict future symptoms, so if you have AMN, your blood samples could help researchers find better ways to understand and manage the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hugo W. Moser Res Inst Kennedy Krieger NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10870302 on NIH RePORTER |
What this research studies
This research aims to discover and validate new blood biomarkers for Adrenomyeloneuropathy (AMN), a neurological condition linked to genetic mutations. By using advanced techniques that analyze various biological molecules in blood plasma, the study seeks to identify markers that can help monitor disease progression and predict future symptoms. The approach combines omics technologies with machine learning to enhance the accuracy of these biomarkers. Patients will provide blood samples over time, allowing researchers to track changes and correlate them with clinical outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Adrenomyeloneuropathy or those who carry mutations in the ABCD1 gene.
Not a fit: Patients without a diagnosis of Adrenomyeloneuropathy or those not carrying ABCD1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better monitoring and prediction of disease progression in patients with Adrenomyeloneuropathy.
How similar studies have performed: Previous research has shown promise in using omics approaches to identify biomarkers for other neurological conditions, suggesting potential success for this novel approach.
Where this research is happening
Baltimore, United States
- Hugo W. Moser Res Inst Kennedy Krieger — Baltimore, United States (Active)
Researchers
- Principal investigator: Fatemi, S. Ali — Hugo W. Moser Res Inst Kennedy Krieger
- Study coordinator: Fatemi, S. Ali
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.